TY  - CHAP
M1  - Book, Section
TI  - Adduct-Forming Agents: Alkylating Agents and Platinum Analogs
A1  - Chabner, Bruce A.
A2  - Chabner, Bruce A.
A2  - Longo, Dan L.
PY  - 2016
T2  - Harrison's Manual of Oncology, 2e
AB  - Since  the  first  clinical  experiments  with  nitrogen  mustard  at  Yale  in  the  early  1940s,  alkylating  agents  have  played  a  primary  role  in  cancer  treatment  (1).  The  early  mustards  have  gradually  been  replaced  by  platinum-based  compounds  in  most  regimens  for  treating  epithelial  cancers,  but  remain  primary  components  in  the  treatment  of  childhood  solid  tumors,  lymphomas,  and  adult  sarcomas,  and  in  high-dose  chemotherapy.  As  a  class,  they  have  the  features  of  the  prototypical  cytotoxic  drugs,  with  broad  antitumor  activity,  but  they  adversely  affect  many  normal  tissues  as  well.  They  share  common  characteristics  of  a  significant  increase  in  response  as  doses  are  escalated:  acute  toxic  effects  on  bone  marrow,  epithelium  of  the  gastrointestinal  tract,  and  hair  follicles;  significant  toxicity  to  lung,  heart,  and  central  nervous  systems  at  bone  marrow  ablative  doses;  and  late  induction  of  myelodysplasia  and  acute  leukemia.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - hemonc.mhmedical.com/content.aspx?aid=1127646482
ER  -